2020 Maryland Statutes
Criminal Law
Title 5 - Controlled Dangerous Substances, Prescriptions, and Other Substances
Subtitle 4 - Schedules
Section 5-404 - Schedule Iii
(a) Schedule III consists of each controlled dangerous substance by whatever official name, common or usual name, chemical name, or brand name designated:
(1) listed in this section;
(2) added to Schedule III by the Department under § 5–202(b) of this title; or
(3) designated as a Schedule III controlled dangerous substance by the federal government unless the Department objects under § 5–202(f) of this title.
(b) (1) Unless specifically excepted or listed in another schedule, a substance is listed in Schedule III if the substance includes a material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system:
(i) those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances;
(ii) benzphetamine;
(iii) chlorphentermine;
(iv) clortermine; and
(v) phendimetrazine.
(2) Subject to paragraph (3) of this subsection, substances in Schedule III include:
(i) a salt of a substance listed in this subsection;
(ii) an optical, position, or geometric isomer of a substance listed in this subsection; or
(iii) a salt of an isomer of a substance listed in this subsection.
(3) Unless listed in another schedule, a salt, isomer, or salt of an isomer described in paragraph (2) of this subsection may be included in Schedule III only if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation.
(c) Unless listed in another schedule, a substance is listed in Schedule III if the substance includes a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
(1) any compound, mixture, or preparation containing:
(i) amobarbital;
(ii) secobarbital;
(iii) pentobarbital; or
(iv) any salt thereof and one or more other active medicinal ingredients that are not listed in any schedule;
(2) any suppository dosage form containing:
(i) amobarbital;
(ii) secobarbital;
(iii) pentobarbital; or
(iv) any salt of any of these drugs and approved by the U.S. Food and Drug Administration for marketing only as a suppository;
(3) except those substances that are specifically listed in other schedules, a substance that contains any quantity of a derivative of barbituric acid, a salt of a derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal);
(4) chlorhexadol;
(5) embutramide;
(6) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug, and Cosmetic Act;
(7) ketamine, its salts, isomers, and salts of isomers;
(8) lysergic acid;
(9) lysergic acid amide;
(10) methyprylon;
(11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA);
(12) sulfondiethylmethane;
(13) sulfonethylmethane;
(14) sulfonmethane; and
(15) tiletamine and zolazepam or any salt thereof, including a tiletamine–zolazepam combination product (trade name Telazol).
(d) As listed in Schedule III under Title 21 of the Code of Federal Regulations, nalorphine 9400.
(e) Unless specifically excepted or unless listed in another schedule:
(1) substances listed in Schedule III include any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(i) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
(ii) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(iv) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(v) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(vi) not more than 100 milligrams of opium per 100 milliliters or per 100 grams, or not more than 5 milligrams per dosage unit; and
(vii) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(2) any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:
(i) buprenorphine; and
(ii) reserved.
(3) if not combined with one or more active medicinal ingredients that are listed in another schedule, substances listed in Schedule III include a suppository dosage form or salt of a suppository dosage that contains:
(i) amobarbital;
(ii) secobarbital; or
(iii) pentobarbital.
(f) (1) Except as provided in paragraph (2) of this subsection, an anabolic steroid consisting of any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, and ethers:
(i) 3beta,17–dihydroxy–5a–androstane;
(ii) 3alpha,17beta–dihydroxy–5a–androstane;
(iii) 5 alpha–androstan–3,17–dione;
(iv) 1–androstenediol (3beta,17beta–dihydroxy–5alpha–androst–1–ene);
(v) 1–androstenediol (3alpha,17beta–dihydroxy–5alpha–androst–1–ene);
(vi) 4–androstenediol (3beta,17beta–dihydroxy–androst–4–ene);
(vii) 5–androstenediol (3beta,17beta–dihydroxy–androst–5–ene);
(viii) 1–androstenedione;
(ix) 4–androstenedione;
(x) 5–androstenedione;
(xi) bolasterone;
(xii) boldenone;
(xiii) boldione;
(xiv) calusterone;
(xv) chlorotestosterone (clostebol);
(xvi) dehydrochloromethyltestosterone;
(xvii) desoxymethyltestosterone;
(xviii) delta1–dihydrotestosterone (17beta–hydroxy–5alpha–androst–1–en–3–one);
(xix) dihydrotestosterone (4–dihydrotestosterone) (17beta–hydroxy–androstan–3–one) (stanolone);
(xx) drostanolone;
(xxi) ethylestrenol;
(xxii) fluoxymesterone;
(xxiii) formebolone;
(xxiv) furazabol;
(xxv) 13beta–ethyl–17beta–hydroxygon–4–en–3–one;
(xxvi) 4–hydroxytestosterone;
(xxvii) 4–hydroxy–19–nortestosterone;
(xxviii) mestanolone (17alpha–methyl–17beta–hydroxy–5–androstan–3–one);
(xxix) mesterolone;
(xxx) methandienone (methandrostenolone) (17alpha–methyl–17beta–hydroxyandrost–1,4–dien–3–one);
(xxxi) methandriol;
(xxxii) methasterone;
(xxxiii) methenolone;
(xxxiv) 17alpha–methyl–3beta, 17beta–dihydroxy–5a–androstane;
(xxxv) 17alpha–methyl–3alpha, 17beta–dihydroxy–5a–androstane;
(xxxvi) 17alpha–methyl–3beta, 17beta–dihydroxyandrost–4–ene;
(xxxvii) 17alpha–methyl–4–hydroxynandrolone;
(xxxviii) methyldienolone;
(xxxix) methyltrienolone;
(xl) methyltestosterone;
(xli) mibolerone;
(xlii) 17alpha–methyl–delta1–dihydrotestosterone;
(xliii) nandrolone;
(xliv) 19–nor–4–androstenediol (3beta, 17beta–dihydroxyestr–4–ene);
(xlv) 19–nor–4–androstenediol (3alpha, 17beta–dihydroxyestr–4–ene);
(xlvi) 19–nor–5–androstenediol (3beta, 17beta–dihydroxyestr–5–ene);
(xlvii) 19–nor–5–androstenediol (3alpha, 17beta–dihydroxyestr–5–ene);
(xlviii) 19–nor–4,9(10)–androstadienedione;
(xlix) 19–nor–4–androstenedione;
(l) 19–nor–5–androstenedione;
(li) norbolethone (13beta, 17alpha–diethyl–17beta–hydroxygon–4–en–3–one);
(lii) norclostebol;
(liii) norethandrolone;
(liv) normethandrolone;
(lv) oxandrolone;
(lvi) oxymesterone;
(lvii) oxymetholone;
(lviii) prostanozol;
(lix) stanozolol;
(lx) stenbolone;
(lxi) testolactone;
(lxii) testosterone;
(lxiii) tetrahydrogestrinone; and
(lxiv) trenbolone.
(2) The following substances are not included in Schedule III:
(i) an estrogen, progestin, or corticosteroid; or
(ii) a substance covered by paragraph (1) of this subsection if:
1. expressly intended for administration through implants to cattle or other nonhuman species; and
2. approved for that use by the U.S. Food and Drug Administration.
(g) Hallucinogenic substances include:
(1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration–approved product; and
(2) reserved.
(h) The Department may not add a substance to Schedule III under § 5–202 of this title unless the Department finds:
(1) a potential for abuse of the substance that is less than that for the substances listed in Schedule I and Schedule II;
(2) well documented and approved medical use of the substance in the United States; and
(3) evidence that abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.
